Lilly schizophrenia drug shows promise in trials

Share this article:

An experimental drug from Eli Lilly reduced schizophrenia symptoms in a clinical trial of 200 patients, according to a paper published in the journal Nature.

The drug, which does not yet have a name, is currently referred to as LY2140023.

Lilly is expected to begin a larger trial for the drug this month. If that trial confirms the results seen so far, it could mark a breakthrough in the treatment of schizophrenia, which affects about 2.5 million US adults.

“This is potentially one giant step forward for patients,” Dr. Jeffrey Lieberman, chairman of the psychiatry department at Columbia University and lead investigator on a federally sponsored clinical trial of schizophrenia medicines told The New York Times. “This drug may turn out to be not just a comparably good antipsychotic agent, but a better antipsychotic agent.”

Dr. Lieberman has not been involved with the development of the Lilly medicine and does not receive any payment or consulting fees from Lilly, the Times noted.

The troubled history of Zyprexa, another antipsychotic from Lilly, could lead regulators to scrutinize the new medicine closely for hidden dangers.

LY2140023 could also have blockbuster potential for Lilly.

Schizophrenia and bipolar disorder medicines are the fourth-best selling class of medicines in the US with sales of $12 billion, plus an additional $8 billion in the ex-US market.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...